2024
Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regions
2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystem